Search results
3 High-Yield Dividend Stocks That Could Soar 22% to 49%, According to Wall Street
Motley Fool via Yahoo Finance· 6 hours agoHowever, Pfizer also faces the looming loss of exclusivity for multiple products. Despite this bad ...
The Motley Fool: Pfizer offers a pfat 6.4% dividend
Dallas Morning News· 5 hours agoShares of Pfizer were recently down more than 35% over the past year — in part because the market’s enthusiasm for its COVID-19 vaccine Comirnaty and...
Is Pfizer Stock A Sell As Shares Hit An 11-Year Low Amid The Search For Its Next Big Break?
Investor's Business Daily· 4 days agoThis is part of an ongoing final-phase study in the Northern and Southern hemispheres. That's a drop...
Pfizer hemophilia gene therapy arrives in US to uncertain future
BioPharma Dive via Yahoo Finance· 2 days agoBeqvez is currently under review in Europe. Pfizer also has an antibody drug for hemophilia A and B...
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
Benzinga via Yahoo Finance· 2 days agoFriday, the FDA approved Pfizer Inc’s (NYSE:PFE) Beqvez (fidanacogene elaparvovec-dzkt) for moderate...
3 Dividend Stocks to Buy and Hold for the Next Decade
Motley Fool via Yahoo Finance· 1 day agoThe company still has another big hurdle to jump, though, with multiple blockbuster drugs losing...
FDA approves Pfizer's first gene therapy for rare inherited bleeding disorder
NBC Philadelphia· 2 days agoThe Food and Drug Administration approved Pfizer's treatment for a rare genetic bleeding disorder,...
EU regulators approve Pfizer antibiotic Emblaveo (NYSE:PFE)
Seeking Alpha· 6 days agoEU regulators have approved Pfizer (PFE) and AbbVie’s (ABBV) antibiotic product Emblaveo for the...
Sigma Planning Corp Lowers Stake in Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 6 days agoSigma Planning Corp lowered its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 52.6% in the fourth quarter, according to its most recent 13F filing with the SEC ...
FDA Approves Second Gene Therapy for Hemophilia B
Medscape· 2 days agoPfizer reported a list price of $3.5 million for its new gene therapy, Beqvez, for adults with this rare bleeding disorder.